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Introduction {#sec1}
============

Natural killer (NK) cells are the founding members of a family of innate lymphoid cells (ILCs) ([@bib7]) that also includes helper ILC1s, ILC2s, and ILC3s ([@bib5]). NK cells protect against infection and mediate antitumor responses via two primary effector functions: production of immunomodulatory cytokines and direct cytotoxicity ([@bib4], [@bib47]). NK cells recognize target cells based on the integration of signals from numerous germline DNA-encoded activating and inhibitory receptors. In general, activating receptors recognize cell stress ligands, while inhibitory receptors recognize major histocompatibility complex (MHC) class I molecules ([@bib23]). In addition, NK cells constitutively express cytokine receptors that support their development and tune their function by ligating activating or inhibitory signals in the surrounding environment ([@bib38], [@bib50]).

The developmental and transcription factor programs of NK cells are distinct from those of helper ILCs. ILC development begins in the bone marrow (BM) from the common lymphoid progenitor (CLP), which gives rise to both the NK and helper ILC lineages. Thereafter, most terminal NK cell maturation takes place in peripheral tissues ([@bib5], [@bib51]). The NK progenitor (NKP) differentiates through several NK cell maturation stages classically characterized based on the presence or absence of the surface markers CD27 and CD11b ([@bib6]). In addition, the activating receptor NKp46, encoded by *Ncr1*, is induced during stage I (CD27^−^CD11b^−^) of differentiation, followed by the integrin CD49b (DX5), and MHC-class-I-recognizing Ly49 activating and inhibitory receptors ([@bib51]). Numerous transcription factors are required to regulate ILC development and promote the different lineages ([@bib21], [@bib24]). NK cells and ILC1s both express T-bet, but of type-1 ILCs, only NK cells express Eomesodermin (Eomes), another T-box transcription factor critical for their development ([@bib7]). Recent data have revealed that NK cells and ILC1s exhibit plasticity depending on their environment and specifically that NK cells can convert to ILC1-like cells in transforming growth factor β (TGF-β)-rich tumors and tissues ([@bib2], [@bib8], [@bib14]), which can involve downregulation of Eomes.

However, the mechanisms whereby modulation of Eomes could alter NK cellular identity and function is unclear. Eomes, like T-bet, regulates gene expression by binding T-box DNA elements. Eomes is generally required for early embryonic development, as evidenced by mice with global Eomes gene deletion exhibiting embryonic lethality ([@bib39]). An important role for Eomes has been demonstrated in CD8 T cell biology; it promotes the development of central memory CD8 T cells as well as the cytotoxic T cell effector program by positively regulating interferon γ (IFN-γ), perforin, and granzyme B ([@bib1], [@bib20], [@bib35]). Eomes is also critical for NK cell development, and mice with hematopoietic- or constitutive NK-cell-specific Eomes deletion display a severe and global decrease in conventional NK cell numbers but preserved ILC1s ([@bib9], [@bib16], [@bib36]). Eomes is expressed by NK cells of all maturation stages, with highest expression in the relatively immature stage II and III populations ([@bib16]). NK cell terminal maturation is thought to rely on T-bet, whose expression increases in terminally mature (stage IV) NK cells, opposite to the decrease in Eomes ([@bib9], [@bib46]). Functionally, Eomes expression correlates with NK cell IFN-γ production *in vivo* ([@bib15]) and *Prf1* transcription ([@bib35]), but T-bet has also been shown to regulate NK cell cytotoxic protein expression ([@bib46]). Thus, the importance of Eomes in mature NK cell homeostasis and function remains unclear.

Studies of Eomes in NK cell homeostasis and function have been limited by a lack of appropriate inducible genetic models. In the constitutive *Ncr1*-*cre* models available (and similarly for *Vav1*-*cre*), *cre-*driven Eomes deletion in immature BM NK cells results in abrogation of NK cell development and thus precludes the study of Eomes in mature NK cell biology ([@bib16], [@bib36]). Indeed, what were once thought to be Eomes-negative NK cells in such constitutive models are now better understood to have been type 1 ILCs ([@bib16]). To overcome this limitation, we developed a type-1-ILC-specific tamoxifen-inducible *cre* mouse model and confirmed its properties using a *Rosa26*-YFP reporter allele. Eomes-floxed mice were crossed to this model in order to elucidate the role of Eomes in mature NK cell biology. Here, we studied the impact of induced Eomes deletion on mature NK cell homeostasis and function. We demonstrate that there are Eomes-dependent (stage II/III) and independent (stage IV) murine NK cell subsets and that loss of Eomes does not reverse NK cell maturation, as has been previously suggested ([@bib16]). In addition, we demonstrate a requirement of ongoing Eomes expression for NK cell cytotoxicity and *in vivo* responses to MHC-I-deficient target cells.

Results {#sec2}
=======

The Ncr1-iCreER^T2^ Tamoxifen-Inducible *cre* Model Specifically Activates *cre* within Type 1 ILCs {#sec2.1}
---------------------------------------------------------------------------------------------------

Mouse models with constitutive type 1 ILC-specific *cre* expression utilizing *Ncr1* regulatory elements ([@bib11], [@bib33]) have limitations. In these models, *cre* expression initiates with normal *Ncr1* gene expression in immature BM stage I NK cells ([@bib49]). Hence, *loxP*-directed excision events occur early in NK cell development, precluding the study of developmentally critical genes in mature NK cells. To overcome this barrier, we developed a type-1-ILC-specific, tamoxifen-inducible *cre* mouse ([Figure 1](#fig1){ref-type="fig"} A) generated by genetic targeting of a tamoxifen-responsive iCreER^T2^ cassette into the *Ncr1* locus. This cassette is linked to NKp46 C-terminal translation via a P2A ribosomal skip site. This *Ncr1*-iCreER^T2^ model was crossed to a reporter allele consisting of a *lox*-stop-*lox* (LSL)-flanked YFP cassette genetically targeted to the *Rosa26* locus in order to track *cre* nuclear activity ([@bib42]). To test the timing of *cre* expression in this model, mice underwent oral gavage with 3 mg tamoxifen for 3 consecutive days ([@bib17], [@bib18]), and 3 days later, YFP expression was analyzed in various tissues ([Figure 1](#fig1){ref-type="fig"}B). YFP expression was observed in NKp46^+^ cells of the blood, spleen, and liver (≥90% YFP^+^) as well as BM and lymph node (LN) (≥80% YFP^+^). YFP expression was restricted to NKp46^+^ cells and not expressed by other hematopoietic lineages, including T cells ([Figure 1](#fig1){ref-type="fig"}B; data not shown). Similar to other iCreER^T2^ models ([@bib22], [@bib29]), mature (8- to 12-week-old) *Ncr1*-iCreER^T2^ mice had small background levels of *cre* nuclear localization (∼5%--10%) in NKp46^+^ cells in the absence of tamoxifen that increased slowly over time ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}). Therefore, in this report, experiments were performed in 8- to 12-week-old mice unless otherwise noted.Figure 1Tamoxifen Induces Robust and Type-1-ILC-Specific *cre* Activity in Mice Harboring the Ncr1-iCreER^T2^ Knockin Locus(A) Schematic depicting the *Ncr1-*iCreER^T2^ locus and mouse model.(B) Mean ± SEM type 1 ILC (NK1.1^+^CD3-) and T cell (CD3^+^) percent YFP^+^ in the blood (Bl), spleen (Sp), bone marrow (BM), lymph node (LN), and liver (Liv) of *Ncr1*-iCreER^T2^ × *Rosa26*YFP^LSL^ mice 2 days following three consecutive daily doses of 3 mg tamoxifen in corn oil (or no tamoxifen \[No Tam\]). Representative flow cytometry data from the spleen of a tamoxifen-treated mouse shown to the right. n = 2--3 mice per group, two independent experiments.(C) *Ncr1*-iCreER^T2^ × *Rosa26*YFP^LSL^ mice were treated with three consecutive daily doses of tamoxifen. Summary data show mean ± SEM. YFP positivity among splenic NK cells, liver NK cells (CD49a^−^ DX5^+^) and liver ILC1 cells (CD49a^+^ DX5^−^) weekly for 5 weeks thereafter. n = 2 mice per group, one experiment.(D) Schematic of tamoxifen regimens.(E) PCR was performed for the presence of Eomes floxed (fl; 730 bp) or WT (620 bp) alleles on heterozygous Eomes^fl/WT^ control genomic DNA (lanes 1 and 2) and YFP^+^ splenic NK cells (NK1.1^+^ CD3^−^, lane 3) or T cells (CD3^+^, lane 4) sorted from ILC-Eomes^Δ/Δ^ mice treated with the Tam-3d regimen. Empty lanes were cropped as shown by the border.(F) Tam-6d-treated Eomes WT and ILC-Eomes^Δ/Δ^ mouse tissues were analyzed for Eomes expression. Summary data show mean ± SEM percent Eomes positivity in YFP^+^NKp46^+^ cells. Representative flow histograms show Eomes protein in Eomes WT (shaded blue line) and ILC-Eomes^Δ/Δ^ NK cells (empty blue line), and NK1.1^−^ CD3^−^ lymphocytes (background, shaded gray) in the spleen and BM. n = 5 Eomes WT mice, 9 ILC-Eomes^Δ/Δ^ mice, two independent experiments.

This model is also useful to assess cellular dynamics within the NKp46^+^ ILC compartment. NK cells and tissue-resident ILC1s were compared in a 3-day tamoxifen "pulse" YFP "chase" experiment. Here, we treated *Ncr1*-iCreER^T2^ × *Rosa26*YFP^LSL^ mice with tamoxifen and then assessed splenic and liver NK cells as well as liver ILC1s for YFP positivity over the next 5 weeks. The proportion of YFP^+^ liver ILC1s remained high (≥90%), consistent with replenishment from NKp46^+^ tissue-resident populations and/or less cellular attrition. In contrast, splenic and liver NK cells displayed considerable turnover, and YFP positivity returned to near-baseline levels by the end of the 5-week period ([Figure 1](#fig1){ref-type="fig"}C). Thus, *Ncr1*-iCreER^T2^ x *Rosa26*YFP^LSL^ mice exhibited robust and specific *cre* activity in NKp46^+^ ILCs after tamoxifen administration, which was tracked in subsequent experiments using YFP. For the remainder of the study, experiments were performed at three time points relative to tamoxifen administration: Tam-3d, Tam-6d, and Tam-9d ([Figure 1](#fig1){ref-type="fig"}D).

Tamoxifen Rapidly Eliminates Eomes in NKp46^+^ Cells of Ncr1-iCreER^T2^ × Eomes^fl/fl^ Mice {#sec2.2}
-------------------------------------------------------------------------------------------

We next crossed *Ncr1*-iCreER^T2^ × *Rosa26*YFP^LSL^ mice to mice with floxed *Eomes* alleles ([@bib53]). *Eomes* allele excision was confirmed in splenocytes of *Ncr1*-iCreER^T2\ KI/WT^ × *Rosa26*YFP^LSL^ × *Eomes* ^fl/fl^ (henceforth ILC-Eomes^Δ/Δ^) mice after the Tam-3d regimen, as PCR analysis of the Eomes locus revealed excision in flow-sorted YFP^+^ NK cells but not YFP^−^ T cells ([Figure 1](#fig1){ref-type="fig"}E). This was verified at the protein level after the Tam-6d regimen using flow cytometry in ILC-Eomes^Δ/Δ^ compared to control NK cells ([Figure 1](#fig1){ref-type="fig"}F). Thus, tamoxifen-induced *cre* efficiently translocated to the nucleus and excised Eomes in mature NK cells within 2 days.

Induced Eomes Deletion Results in a Rapid Loss of NK Cells, Most Prominently Stage III {#sec2.3}
--------------------------------------------------------------------------------------

To assess the impact of induced Eomes deletion on the NK cell compartment, we treated ILC-Eomes^Δ/Δ^ and control mice with the Tam-6d regimen and then assessed NK cell numbers and maturation. We observed a significant decrease in global YFP^+^ NK cell numbers in ILC-Eomes^Δ/Δ^ compared to wild-type (WT) control mice in all tissues examined (blood, spleen, BM, LN, and liver; [Figure 2](#fig2){ref-type="fig"} A). Notably, induced Eomes deletion had a particularly profound effect on less mature stage II (CD27^+^CD11b^−^) and stage III (CD27^+^CD11b^+^) NK cells. Stage III NK cells, in particular, were significantly decreased in number and percentage in all tissues analyzed ([Figure 2](#fig2){ref-type="fig"}B). While stage IV (CD27^−^CD11b^+^) NK cell numbers were reduced in the blood, BM, and LN in ILC-Eomes^Δ/Δ^ mice, their relative proportion increased in all tissues except the liver, where it was unchanged. As expected, Eomes-dependent NK cells were decreased in both the proportion of YFP^+^ NKp46^+^ cells and absolute number in the liver, while the proportion of Eomes-independent ILC1s increased, but numbers remained unchanged ([Figure 2](#fig2){ref-type="fig"}C) ([@bib41]). Despite evidence that Eomes and T-bet negatively cross-regulate one another ([@bib9]), we did not observe increased T-bet protein levels in ILC-Eomes^Δ/Δ^ NK cells ([Figure 2](#fig2){ref-type="fig"}D). Thus, induced *Eomes* deletion negatively affects NK cell numbers and homeostasis, particularly those of the stage III subset.Figure 2Induced Eomes Deletion Results in a Significant Decrease in Global NK Cell Numbers, witha Particularly Profound Loss of Stage III NK Cells(A) Mean ± SEM. YFP^+^ NKp46^+^ cell percentage of lymphocytes and number in the blood (Bl; per mL), spleen (Sp), BM (per femur), LN (per inguinal LN), or liver (Liv) of ILC-Eomes^Δ/Δ^ versus WT mice following the Tam-6d regimen.(B) Summary data show mean ± SEM. YFP^+^ NK1.1^+^ cell stage-specific percentages and numbers in ILC-Eomes^Δ/Δ^ or Eomes WT mice in the five different tissues. ILC1s are included in liver gating. Representative flow cytometry data are shown for the spleen.(C) Summary data show mean ± SEM. YFP^+^ NK cell (CD49a^−^ DX5^+^) versus ILC1 (CD49a^+^ DX5^−^) percentage and numbers in the liver. n = 9 ILC-Eomes^D/D^ mice, 5 Eomes WT mice, two independent experiments.(D) Summary data show mean ± SEM. T-bet MFI in YFP^+^ ILC-Eomes^Δ/Δ^ and WT NKp46^+^ cells across the type 1 ILC compartment, normalized to the mean T-bet MFI of ILC-Eomes^Δ/Δ^ NKp46^+^ cells in each tissue. n = 9 ILC-Eomes^Δ/Δ^ mice, 5 Eomes WT mice, two independent experiments. Data were compared using false-discovery-rate-corrected t tests.\*p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Loss of Stage III NK Cells in ILC-Eomes^Δ/Δ^ Mice Results from Apoptosis and Altered Cell-Cycling Dynamics {#sec2.4}
----------------------------------------------------------------------------------------------------------

We hypothesized that the decrease in NK cell numbers observed following Eomes deletion could be the result of enhanced apoptosis or altered cell cycling. This was tested at an earlier time point after tamoxifen gavage (Tam-3d), when cells undergoing apoptosis or attempting to proliferate may still be quantifiable. At this time point, \>70% of splenic ILC-Eomes^Δ/Δ^ and control NK cells were YFP^+^, Eomes protein was nearly absent, and reductions in NK cells had started but were more modest compared to the Tam-6d time point ([Figures 3](#fig3){ref-type="fig"}A and 3B). A significantly greater fraction of apoptotic (Annexin V^+^) stage III NK cells were present in the spleen and BM of ILC-Eomes^Δ/Δ^ compared to WT mice ([Figure 3](#fig3){ref-type="fig"}C). This was associated with a significant increase in caspase activation in splenic stage III NK cells of ILC-Eomes^Δ/Δ^ compared to control mice ([Figure 3](#fig3){ref-type="fig"}D). To further understand this apoptosis phenotype, we performed unbiased RNA sequencing (RNA-seq) of flow-sorted stage II, III, and IV ILC-Eomes^Δ/Δ^ and WT splenic NK cells. Gene set enrichment analysis (GSEA) of the RNA-seq data revealed significant enrichment of the Hallmark Apoptosis Pathway in ILC-Eomes^Δ/Δ^, compared to WT, stage II NK cells ([Figure 3](#fig3){ref-type="fig"}E). This enrichment was not observed in stage III or IV NK cell comparisons ([Figure S2](#mmc1){ref-type="supplementary-material"}). These data are consistent with the observed loss of stage III NK cells, as they suggest that induced Eomes deletion activates apoptotic machinery in stage II NK cells that die at stage III.Figure 3Induced Eomes Deletion Results in Increased Stage III NK Cell Apoptosis and Altered Cell-Cycling DynamicsILC-Eomes^Δ/Δ^ and Eomes WT mice were treated with the Tam-3d regimen, and then apoptosis and cell cycling dynamics were assessed.(A) YFP expression, percentage, and number of splenic ILC-Eomes^Δ/Δ^ and Eomes WT NK cells. n = 5--6 mice per group, two independent experiments.(B) Mean ± SEM percentage of Eomes^+^ splenic NK cells. Representative flow histogram shows Eomes protein in splenic Eomes WT (shaded blue line) and ILC-Eomes^Δ/Δ^ NK cells (empty blue line), and NK1.1- CD3- lymphocytes (background, shaded gray). n = 8 ILC-Eomes^Δ/Δ^ mice, 4 Eomes WT mice, two independent experiments.(C) Mean ± SEM. Annexin V^+^ ILC-Eomes^Δ/Δ^ or Eomes WT NK cells by stage in the BM and spleen. n = 12--17 mice per group, four to seven independent experiments.(D) Mean ± SEM percent of ILC-Eomes^Δ/Δ^ or Eomes WT splenic stage II or III NK cells with activated poly-caspase expression. n = 5--6 mice per group, two independent experiments.(E) GSEA of RNA-seq data from ILC-Eomes^Δ/Δ^ and Eomes WT stage II NK cells. An enrichment plot for the hallmark apoptosis pathway is shown to the left, with all significantly enriched or downregulated pathways shown to the right.(F) Mean ± SEM proportion of G0, G1, and S/G2/M stage III Eomes WT and ILC-Eomes^Δ/Δ^ NK cells in the spleen and BM, with representative flow plots shown. n = 9--12 mice per group, three or four independent experiments.(G) Mean ± SEM proportion of G0, G1, and S/G2/M stage III ILC-Eomes^Δ/Δ^ and Eomes WT NK cells in the spleen and BM one day after the Tam-3d regimen. n = 6 mice per group, two independent experiments. Data were compared using t tests with false discovery rate correction where appropriate.\*p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

ILC-Eomes^Δ/Δ^ and WT NK cells were also co-stained for Ki67 (a marker of proliferation) and DNA content to assess cell-cycle dynamics ([Figures 3](#fig3){ref-type="fig"}F, 3G, and [S3](#mmc1){ref-type="supplementary-material"}A). The cell-cycle distribution of bulk, stage II, and stage IV NK cells was identical between WT and ILC-Eomes^Δ/Δ^ mice in the spleen and BM ([Figure S3](#mmc1){ref-type="supplementary-material"}B). However, a significantly greater percentage of stage III NK cells were in G1 in ILC-Eomes^Δ/Δ^ compared to WT mice ([Figure 3](#fig3){ref-type="fig"}F). No cells progressed to S/G2/M, however, even when analyzed an additional day after the Tam-3d regimen ([Figure 3](#fig3){ref-type="fig"}G). This suggests that induced Eomes deletion promotes a G0 to G1 transition in stage III NK cells, yet the cell cycle is unable to progress beyond that point, possibly due to cell-cycle-arrest-related apoptosis. Eomes-deleted NK cells are capable of cell division, however, as demonstrated via transfer experiments into a homeostatic proliferation environment ([Figure S4](#mmc1){ref-type="supplementary-material"}). Here, both ILC-Eomes^Δ/Δ^ and Eomes WT YFP^+^ splenic NK cells showed robust and comparable proliferation 14 days post-transfer into Rag2^−/−^γc^−/−^ recipient mice ([Figure S4](#mmc1){ref-type="supplementary-material"}B). While restrictions on our flow panel did not allow for stage-specific analyses, given the deleterious effect of Eomes on stage III NK cell numbers, we hypothesize that the proliferated ILC-Eomes^Δ/Δ^ NK cells were largely stage II and IV. Short-term proliferation of ILC-Eomes^Δ/Δ^ and WT YFP^+^ NK cells after 4 days *in vivo* was also similar but significantly reduced compared to *cre*-negative NK cells, suggesting that induction of *cre* concurrent with a strong proliferation signal may alter normal cellular proliferation ([Figure S4](#mmc1){ref-type="supplementary-material"}A) ([@bib26]). Collectively, these findings suggest that Eomes loss promotes stage III apoptosis either by directly activating apoptotic genes in precursor stage II NK cells or as a result of cell-cycle arrest.

IL-15 Signaling Is Altered in Stage II and III NK Cells as a Result of Induced Eomes Deletion but Does Not Account for Stage III NK Cell Loss {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------------------------

Interleukin-15 (IL-15) is the major cytokine involved in NK cell development, survival, and proliferation. Three major pathways are activated downstream of the IL-15 receptor (IL-15R): JAK/STAT (JAK1/3 and STAT3/5), mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K) ([@bib30]). STAT5, in particular, is known to be critical for NK cell survival, since it promotes the transcription of anti-apoptotic molecules like Bcl-2 and Mcl-1 ([@bib19], [@bib37]). Since Eomes is known to regulate the β chain of the IL-15R (CD122) ([@bib20]), we hypothesized that induced Eomes deletion resulted in decreased expression of the intermediate-affinity (β/γ) IL-15R and thus decreased IL-15 signaling and STAT5 phosphorylation *in vivo*, leading to stage III NK cell apoptosis. Indeed, a significant decrease in CD122 expression on both stage II/III and stage IV Tam-3d-treated ILC-Eomes^Δ/Δ^ compared to WT NK cells was observed ([Figure 4](#fig4){ref-type="fig"} A). We used phospho-flow cytometry to interrogate activation of downstream signaling pathways in response to low-dose (10 ng/mL) and high-dose (100 ng/mL) IL-15 in NK cells from WT and ILC-Eomes^Δ/Δ^ mice treated with the Tam-3d regimen ([Figure 4](#fig4){ref-type="fig"}B). Unexpectedly, we observed no defect in pSTAT5 activation at either IL-15 concentration tested and, accordingly, no difference in Bcl-2 protein expression between ILC-Eomes^Δ/Δ^ and WT NK cells ([Figure S5](#mmc1){ref-type="supplementary-material"}A). In contrast, pERK and pAkt median fluorescence intensity (MFI) was decreased in ILC-Eomes^Δ/Δ^ compared to WT stage II/III NK cells in response to low-dose, but not high-dose, IL-15. This is consistent with higher levels of IL-15 being required to activate these pathways, compared to STAT5, in murine NK cells ([@bib28]). While they are not considered to be the principal regulators of NK cell apoptosis, the PI3K/Akt/mTOR and MAPK pathways have been shown to play important roles in promoting NK cell survival ([@bib19]). However, stage III NK cells were not rescued in mice that received exogenous IL-15 concomitantly with tamoxifen ([Figures S5](#mmc1){ref-type="supplementary-material"}B--S5D). Thus, the negative effect of Eomes deletion on stage III NK cell survival is likely not the result of impaired IL-15 signaling.Figure 4Induced Eomes Deletion Results in Modest Differences in IL-15 Signaling(A) Mean ± SEM. CD122 MFI on stage II/III (CD27^+^) versus stage IV (CD27^−^CD11b^+^) splenic NK cells from Eomes WT and ILC-Eomes^Δ/Δ^ mice treated with the Tam-3d regimen. Representative flow histograms also shown. n = 6 mice per group, two independent experiments.(B) Mean ± SEM pSTAT5, pERK, and pAkt MFI fold change over baseline (unstimulated) in splenic NK cells from Eomes WT and ILC-Eomes^Δ/Δ^ mice treated with the Tam-3d regimen. Cells were stimulated with 10 or 100 ng/mL IL-15 for 15 min (pSTAT5) or 1 h (pERK, pAkt). n = 7--10 mice per group, three or four independent experiments. Data were compared using t tests.\*p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Induced Eomes Deletion Impairs NK Cell Maturation *In Vivo* {#sec2.6}
-----------------------------------------------------------

The PI3K and MAPK pathways are involved in other aspects of NK cell homeostasis, including maturation ([@bib45]). We hypothesized that the stage III NK cell defect might also be due to impaired maturation from precursor stage II cells. To test this hypothesis, we treated ILC-Eomes^Δ/Δ^ and WT mice with the Tam-3d regimen then sorted YFP^+^ CD27^+^ (stage II/III) or YFP^+^ CD27^−^ CD11b^+^ (stage IV) NK cells, transferred them into congenic recipients, and allowed them to mature for 2 weeks *in vivo* ([Figure 5](#fig5){ref-type="fig"} A) ([@bib44]). Stage IV NK cells from both ILC-Eomes^Δ/Δ^ and WT control mice were stable and remained stage IV after 2 weeks ([Figure 5](#fig5){ref-type="fig"}B), contrary to previous results utilizing *ex vivo* TAT-*cre*-induced Eomes deletion ([@bib16]). However, the majority of ILC-Eomes^Δ/Δ^ NK cells that were stage II/III at the time of transfer were stage II after 2 weeks *in vivo*, with only a small number of stage IV NK cells developing. This was in contrast to WT cells that showed expected *in vivo* maturation ([Figures 5](#fig5){ref-type="fig"}B and 5C). To account for any bias introduced by sorting on YFP^+^ cells, this experiment was repeated by sorting stage II/III or stage IV cell trace violet (CTV)-labeled NK cells from ILC-Eomes^Δ/Δ^ or CD45.1 WT mice prior to tamoxifen, and co-transferring cells of the same stage into CD45.2 recipients. The recipient mice were then treated with 3 days of tamoxifen, and *in vivo* maturation was assessed 2 weeks later with similar results ([Figure S6](#mmc1){ref-type="supplementary-material"}). These *in vivo* maturation experiments indicate that Eomes is required for normal stage II to III NK cell maturation. Thus, the particularly profound defect in stage III NK cells following Eomes deletion also arises from a stage II to III maturation block.Figure 5Eomes Is Required for Normal NK Cell Maturation(A) ILC-Eomes^Δ/Δ^ and Eomes WT mice were treated with the Tam-3d regimen. Splenic NK cells were sorted to YFP^+^CD27^+^ (stage II/III) or YFP^+^CD27^−^CD11b^+^ (stage IV) and transferred into CD45.2 WT recipients. 2 weeks later, YFP^+^ cell maturation was assessed.(B) Stage distribution of ILC-Eomes^Δ/Δ^ or Eomes WT sorted stage II/III or IV NK cells before (light blue) or 2 weeks after transfer (dark blue).(C) Representative flow cytometry data showing maturation of stage II/III ILC-Eomes^Δ/Δ^ or Eomes WT NK cells after 2 weeks *in vivo*. N ≥ 3 pooled mice per group, three independent experiments. Data were compared using t tests.\*p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Eomes Deletion Impairs NK Cell Cytotoxicity, but Not Cytokine Production {#sec2.7}
------------------------------------------------------------------------

ILC-Eomes^Δ/Δ^ mice were next used to assess the impact of Eomes deletion on mature NK cell function. To assess *ex vivo* cytotoxic responses, we treated ILC-Eomes^Δ/Δ^ and WT mice with the Tam-3d regimen, and on the 2^nd^ day of tamoxifen also administered poly(I:C), a synthetic Toll-like receptor 3 (TLR3) agonist that activates NK cells ([@bib12]). 24 h later, splenocytes were harvested, and enriched NK cells were used as effectors in flow-based killing assays against MHC-class I-deficient RMA-S leukemia targets. We observed a significant decrease in RMA-S killing by ILC-Eomes^Δ/Δ^ NK cells at both effector-to-target ratios examined ([Figure 6](#fig6){ref-type="fig"} A). NK cells were equally enriched in the two groups ([Figure 6](#fig6){ref-type="fig"}B), demonstrating that the killing defect was not due to different numbers of ILC-Eomes^Δ/Δ^ versus control NK cells, but rather was cell-intrinsic. NK cell killing of target cells involves the targeted release of cytotoxic-protein-containing granules. Granzyme B protein levels were not affected by induced Eomes deletion ([Figure 6](#fig6){ref-type="fig"}C), consistent with prior reports showing robust granzyme B protein levels in Eomes-deficient ILCs ([@bib16]). However, RNA-seq analysis revealed a ≥2-fold decrease in perforin mRNA in stage II and III ILC-Eomes^Δ/Δ^ relative to WT NK cells ([Figure S7](#mmc1){ref-type="supplementary-material"}A), consistent with prior reports of NK cell perforin regulation by Eomes ([@bib20]). Indeed, we performed Eomes chromatin immunoprecipitation sequencing (ChIP-seq) on primary, IL-15-expanded murine NK cells and confirmed the *Prf1* transcription start site to be a direct target of Eomes ([Table S1](#mmc2){ref-type="supplementary-material"}). In addition, since inducible Eomes deletion might impact the NK cell granular exocytosis pathway more globally ([@bib13]), we performed GSEA of our RNA-seq data for the Kyoto Encyclopedia of Genes and Genomes (KEGG) NK-cell-mediated cytotoxicity pathway and observed significant downregulation of this pathway in ILC-Eomes^Δ/Δ^ compared to WT NK cells of all stages ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Thus, induced Eomes deletion appears to affect several components of the NK cell cytotoxic program, including perforin.Figure 6Induced Eomes Deletion Does Not Significantly Alter NK Cell Functional Responses but Impairs *Ex Vivo* Cytotoxicity(A and B) ILC-Eomes^Δ/Δ^ or Eomes WT mice were treated with the Tam-3d regimen. On day 2 of tamoxifen, mice were also administered 300 μg poly(I:C) intraperitoneally (i.p.) 24 h later, NK cells were enriched from splenocytes pooled from 2-3 mice per group and used in a flow-based killing assay against RMA-S targets. (A) Percent specific killing of RMA-S cells at the indicated effector/target ratios and (B) mean ± SEM. NK cell percentage of CD45^+^ cells from splenocytes used in the killing assay. n = 3 sets of pooled mice per group, three independent experiments.(C) Mean ± SEM granzyme B percent positive and MFI of NK cells immediately before (in the blood) and 24 h after (in the spleen) poly(I:C). n = 7--11 mice per group, two or three independent experiments.(D and E) Splenocytes from ILC-Eomes^Δ/Δ^ or Eomes WT mice treated with the Tam-3d, Tam-6d, or Tam-9d regimens were stimulated with plate-bound anti-NK1.1, IL-12 (10 ng/mL) + IL-15 (10 ng/mL) or YAC-1 lymphoma targets (10:1 effector:target \[E:T\]) in a 6-h functional assay. Summary data show (D) overall mean ± SEM percent IFN-γ or CD107a positive NK cells and (E) IFN-γ and CD107a positivity by stage in response to the different stimuli. n = 8--9 mice per group, three independent experiments. Data were compared using false-discovery-rate-corrected t tests.\*p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To complement cytotoxicity assessments, we examined *in vitro* NK cell cytokine and degranulation (surface CD107a) responses after stimulation. A time course of ILC-Eomes^Δ/Δ^ versus WT NK cell function following the Tam-3d, Tam-6d, or Tam-9d regimens was utilized ([Figures 6](#fig6){ref-type="fig"}D and 6E). At each time point, we observed no differences in ILC-Eomes^Δ/Δ^ versus WT NK cell degranulation or IFN-γ production in response to cytokine (IL-12/15) stimulation, YAC-1 lymphoma, or activating receptor NK1.1 ligation ([Figure 6](#fig6){ref-type="fig"}D). We also investigated stage-specific ILC-Eomes^Δ/Δ^ versus WT NK cell function, and similarly, there were few substantial differences. The most consistent was a modest deficit in ILC-Eomes^Δ/Δ^ stage II NK cell functional responses to anti-NK1.1 ligation ([Figure 6](#fig6){ref-type="fig"}E). Thus, *in vitro* NK cell cytokine and degranulation responses were largely preserved upon induced Eomes deletion, despite reduced *ex vivo* cytotoxicity.

Induced Eomes Deletion Impairs Rejection of MHC-Class-I-Deficient Splenocytes *In Vivo* {#sec2.8}
---------------------------------------------------------------------------------------

To investigate the importance of induced Eomes deletion on NK cell function *in vivo*, we assessed the ability of NK cells to reject MHC-class I-deficient targets ([@bib3]). ILC-Eomes^Δ/Δ^ and WT mice were treated with the Tam-3d regimen and injected intravenously (i.v.) on day 3 with a 50:50 mix of WT and β2 m^−/−^ (MHC-class-I-deficient) splenocytes. 18--20 h later, mice were sacrificed and the WT:β2 m^−/−^ ratio of transferred cells in the spleen assessed ([Figure 7](#fig7){ref-type="fig"} ). β2 m^−/−^ cells were efficiently rejected in WT mice, but no rejection occurred in ILC-Eomes^Δ/Δ^ mice ([Figures 7](#fig7){ref-type="fig"}A--7C). Indeed, the WT:β2 m^−/−^ ratio of transferred cells in the spleen after 18--20 h was the same for ILC-Eomes^Δ/Δ^ mice as it was for negative control mice that had been NK cell depleted. Alterations in the NK cell Ly49 repertoire could underlie this finding, and prior publications have demonstrated that Eomes is required for the generation of a diverse Ly49 repertoire, but not its maintenance ([@bib16]). However, there were no substantial differences in Ly49 receptor expression between ILC-Eomes^Δ/Δ^ and WT NK cells ([Figure 7](#fig7){ref-type="fig"}D), suggesting that Ly49 alterations were unlikely to account for the impaired *in vivo* rejection phenotype. Thus, the impaired *ex vivo* cytotoxicity of ILC-Eomes^Δ/Δ^ NK cells was manifest *in vivo*, as the cells showed no ability to reject MHC-class-I-deficient targets.Figure 7Inducible Eomes Deletion Impairs *In Vivo* NK Cell Rejection of β2 m^−/−^ Splenocytes(A--C) Eomes WT and ILC-Eomes^Δ/Δ^ mice were treated with the Tam-3d regimen. On day 3, mice received tamoxifen as well as 2 × 10^6^ WT and 2 × 10^6^ β2 m^−/−^ splenocytes via tail vein injection. Transferred splenocytes were CFSE^+^ and differentially labeled with CTV. 18--20 h later, mice were sacrificed, and the WT versus β2 m^−/−^ content of CFSE^+^ splenocyte events was assessed. As a control for NK-independent killing, some mice received 200 μg anti-NK1.1 antibody i.p. 2 days before splenocyte transfer. (A) β2 m^−/−^ versus WT composition of transferred (CFSE^+^) splenocytes 18--20 h post-transfer with representative flow in (B). (C) Mean ± SEM percent rejection by ILC-Eomes^Δ/Δ^ versus WT mice. Percent rejection = (1 − \[(ratio WT:β2 m ^−/−^)~experimental~/(ratio WT:β2 m^−/−^)~NK\ depleted~\]) × 100. n = 10 Eomes WT mice, 10 ILC-Eomes^Δ/Δ^ KO mice, 6 NK-depleted mice, two independent experiments.(D) Ly49 repertoire of Eomes WT and ILC-Eomes^Δ/Δ^ YFP^+^ NK cells following the Tam-3d regimen. n = 8--11 mice, three or four independent experiments. Data were compared using t tests with false discovery rate correction where appropriate.\*p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Discussion {#sec3}
==========

The role of Eomes in mature NK cell homeostasis and function has been incompletely understood, in large part due to a lack of inducible, conditional genetic models. Constitutive *Ncr1-cre* and *Vav*-*cre* models have conclusively demonstrated that DX5^+^ NK cells fail to develop in the absence of Eomes ([@bib16], [@bib36]). While some studies attempted to investigate the functional and phenotypic properties of cells that did develop in these models, particularly in the liver, these results are challenging to interpret in light of our current understanding that these were ILC1s and not Eomes-deficient NK cells. Since constitutive *Ncr1*-*cre* and *Vav*-*cre* models delete genes early in NK cell development (stage I or earlier), they preclude the study of genes required for normal NK cell ontogeny (like Eomes). In addition, global inducible models are complicated by cell-extrinsic effects and the requirement for adoptive transfer experiments ([@bib27]). To overcome these limitations, we developed a highly penetrant, tamoxifen-inducible type-1-ILC-specific *cre* mouse. A transgenic inducible model that expressed *cre* in a small minority of NKp46^+^ cells was previously reported but lacked highly penetrant type 1 ILC-specific gene targeting ([@bib32]). The *Ncr1*-iCreER^T2^ reported here results in near-complete Eomes protein loss throughout the NK cell compartment in 2 days and permitted the demonstration of a persistent requirement for Eomes in mature NK cell homeostasis and function. Like most *cre*-*loxP* systems, our *Ncr1*-iCreER^T2^ model has limitations that must be considered during experimental design, including small background levels of *cre* expression in older mice and potentially altered proliferation kinetics. These limitations reinforce the importance of having a reporter for *cre* activity in experimental mice.

Eomes deletion negatively affected NK cell homeostasis, with a particularly profound effect on stage III NK cells. We determined that the stage III deficit arose from several mechanisms, including increased apoptosis (likely caspase dependent), altered cell cycling, and impaired maturation from stage II NK cells. IL-15-induced activation of PI3K/Akt/mTOR and MAPK was impaired in response to low-dose IL-15 in ILC-Eomes^Δ/Δ^ ΝΚ cells, yet exogenous IL-15 failed to rescue stage III NK cells *in vivo*. Thus, Eomes appears to regulate NK cell survival via mechanisms that are not rescued by exogenous IL-15. Indeed, we observed enrichment of apoptosis-related genes specifically in ILC-Eomes^Δ/Δ^ compared to WT stage II NK cells, which likely undergo cell death as they transition to stage III. These data reveal a role for Eomes in regulating hematopoietic cell apoptosis, a greater understanding of which could potentially lead to novel ways of supporting NK cells in the setting of adoptive transfer. The deficit in PI3K and MAPK activation by IL-15 at physiologic cytokine levels could, however, contribute to the maturation defect observed in stage II ILC-Eomes^Δ/Δ^ ΝΚ cells ([@bib45]). Importantly, and in contrast to prior models that induced Eomes deletion *ex vivo* in mature NK cells ([@bib16]), we demonstrate that mature (stage IV) NK cells are largely Eomes independent and do not revert to an immature state if Eomes is lost. In addition, although we saw no overall deficits in NK cell homeostatic proliferation upon induced Eomes deletion, stage-specific analyses as well as investigations of activation or inflammation-driven proliferation were not performed and will be important to fully appreciate the impact of Eomes deletion on NK cell proliferation. For the last decade, NK cell maturation has largely been classified based on CD27 and CD11b expression ([@bib6]). Our findings suggest that an alternate way of characterizing NK cell maturation is based on Eomes dependence. As such, stage II/III NK cells are Eomes dependent, while stage IV NK cells are predominantly Eomes independent. Terminally mature NK cells downregulate Eomes and upregulate T-bet, and so we hypothesize that stage IV NK cell homeostasis is T-bet dependent. Additional studies utilizing the inducible *cre* model with both T-bet and Eomes floxed alleles will clarify these T-box transcription factor requirements.

Functionally, we observed that induced Eomes deletion impaired NK cell killing, as evidenced by both *in vivo* rejection of MHC-class-I-deficient splenocytes and *ex vivo* killing of tumor target cells. While the decreased NK cell number arising from induced Eomes deletion could be a contributing factor, the killing defect *in vivo* was disproportionate to the NK cell deficit, and the *ex vivo* killing assay was performed with equal NK cell numbers. Thus, Eomes deletion impairs NK cell killing *in vivo* and *ex vivo* via NK-cell-intrinsic mechanisms. NK cells kill via exocytosis of cytotoxic-protein-containing granules and via the ligation of death receptors on target cells. Ongoing Eomes-regulated transcription is not required for short-term granzyme B protein expression, as we observed no reduction in granzyme B protein levels in ILC-Eomes^Δ/Δ^ compared to WT NK cells. In contrast, RNA-seq revealed a significant reduction in perforin mRNA in ILC-Eomes^Δ/Δ^ stage II and III NK cells compared to WT, and Eomes ChIP-seq confirmed *Prf1* to be an NK cell target of Eomes. While we were unable to quantify perforin protein due to technical limitations of available flow-based antibodies, decreases in perforin protein are likely to have occurred given the perforin sensitivity of RMA-S cells ([@bib48]). However, perforin mRNA was unchanged by induced Eomes deletion in stage IV NK cells, and since these cells are major NK cytotoxic mediators, this suggested that other components of the NK cell cytotoxic machinery may have been altered by induced Eomes deletion. Indeed, we observed downregulation of the KEGG NK-cell-mediated cytotoxicity pathway in ILC-Eomes^Δ/Δ^ NK cells of all stages, demonstrating a broader role for Eomes in regulating NK cell cytotoxicity. It is also possible that alterations in death receptor ligand expression contributed to the killing defects observed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), in particular, is expressed on tissue-resident, Eomes-negative ILC1s, so it is possible that it is upregulated upon Eomes deletion. However, RMA-S cells are relatively TRAIL and FasL resistant in short-term killing assays ([@bib40], [@bib48]). Thus, while it will be important to investigate death receptor ligand expression and function on ILC-Eomes^Δ/Δ^ NK cells in the future, they likely did not contribute substantially to our cytotoxicity phenotype.

Unlike the cytotoxicity results, short-term NK cell degranulation and IFN-γ production were largely unaltered by induced Eomes deletion. It has been suggested that Eomes may be important for sustained NK cell functional responses and that Eomes downregulation, for example in cells infiltrating a tumor, might be a sign of NK cell exhaustion ([@bib15]). As such, it will be informative to perform studies of sustained NK cell function (such as infection with murine cytomegalovirus \[MCMV\] or tumors) using our inducible *cre* system to assess the role of Eomes in these types of NK cell responses. Intriguingly, our ChIP-seq data, performed on IL-15-expanded NK cells, revealed a weak binding peak near the granzyme B promoter ([Table S1](#mmc2){ref-type="supplementary-material"}). We speculate that in settings of sustained activation, Eomes may play a role in regulating the expression of this cytotoxic protein as well and that this may be a mechanism through which Eomes loss contributes to NK cell exhaustion. A greater understanding of how Eomes deletion affects the entire NK-cell-activating (e.g., NKG2D and NKp30) and inhibitory (e.g., NKG2A) repertoire will also be important to fully understand virus and tumor model findings.

This conditional, inducible *cre* model has many potential applications beyond the study of developmentally critical genes, which will make it important for addressing other outstanding questions in the type 1 ILC field. For example, it could be used to study NK cell populations that arise only after specific physiologic triggers, such as MCMV-specific innate memory or cytokine-induced memory-like NK cells. In addition, since we demonstrated that ILC1s regenerate at a much slower rate than NK cells, or from NKp46^+^ precursors, this model may be useful to selectively ablate genes within ILC1s, thereby permitting studies of the *in vivo* functions of these distinct but related cell types. Thus, this study provides a critical tool for the field to address new questions and avenues of investigation in type 1 ILC biology.

Limitations {#sec3.1}
-----------

Submission of this manuscript occurred during the SARS-CoV-2 pandemic, limiting our ability to perform experiments to address all issues raised during peer review. Some experiments, while of great interest, were beyond the feasible scope of the manuscript in light of restrictions imposed to contain the pandemic. These issues will be addressed in future studies, including (1) whether death receptor ligands (TRAIL and FasL) are differentially expressed on ILC-Eomes^Δ/Δ^ versus control NK cells and whether they contribute significantly to ILC-Eomes^Δ/Δ^ NK cell cytotoxicity; (2) whether induced Eomes deletion alters sustained NK cell function, as determined by an *in vivo* virus or tumor model; (3) if the expression of other activating and inhibitory receptors (e.g., NKG2D, NKp30, and NKG2A) differs between ILC-Eomes^Δ/Δ^ and control NK cells; (4) evaluation of perforin protein in addition to decreased mRNA in stage II and III ILC-Eomes^Δ/Δ^ NK cells; and (5) a comprehensive assessment of the impact of Eomes deletion on NK cell proliferation.

In summary, we developed a type-1-ILC-specific inducible *cre* mouse to identify a stage-specific requirement for Eomes in regulating NK cell homeostasis and cytotoxicity. In addition to elucidating the role of Eomes in mature NK cell biology, this study highlights the importance of complementing studies of constitutive *cre* with inducible models in order to elucidate the biological roles of genes at all stages of cellular development. As such, we anticipate that the *Ncr1*-iCreER^T2^ model will provide important insights into the nascent field of type 1 ILC biology.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**PE-eFluor 610 CD3e anti-mouse mAb (145-2C11)Thermo FischerCat\# 61-0031-82; RRID:[AB_2574514](nif-antibody:AB_2574514){#interref70}APC CD11b anti-mouse mAb (M1/70)Thermo FischerCat\# 17-0112-82; RRID:[AB_469343](nif-antibody:AB_469343){#interref75}PE-Cyanine7 CD27 anti-mouse mAb (LG.7F9)Thermo FischerCat\# 25-0271-82; RRID:[AB_1724035](nif-antibody:AB_1724035){#interref80}APC CD49b anti-mouse mAb (DX5)Thermo FischerCat\# 17-5971-82; RRID:[AB_469485](nif-antibody:AB_469485){#interref85}eFluor660 CD107a anti-mouse mAb (1D4B)Thermo FischerCat\# 50-1071-82; RRID:[AB_11149501](nif-antibody:AB_11149501){#interref90}eFluor450 CD122 anti-mouse mAb (TM-b1)Thermo FischerCat\# 48-1222-82; RRID:[AB_2016697](nif-antibody:AB_2016697){#interref95}PerCP-eFluor710 EOMES anti-mouse mAb (Dan11mag)Thermo FischerCat\# 46-4875-82; RRID:[AB_10597455](nif-antibody:AB_10597455){#interref100}APC Granzyme B anti-human mAb (GB12)Thermo FischerCat\# MHGB05; RRID:[AB_10373420](nif-antibody:AB_10373420){#interref105}PE IFN gamma anti-mouse mAb (XMG1.2)Thermo FischerCat\# 12-7311-82; RRID:[AB_466193](nif-antibody:AB_466193){#interref110}APC Ki-67 anti-mouse mAb (SolA15)Thermo FischerCat\# 17-5698-82; RRID:[AB_2688057](nif-antibody:AB_2688057){#interref115}APC Ly-49H anti-mouse mAb (3D10)Thermo FischerCat\# 17-5886-82; RRID:[AB_2688057](nif-antibody:AB_2688057){#interref120}PerCP-eFluor710 Ly-49G2 anti-mouse mAb (4D11)Thermo FischerCat\# 46-5781-82; RRID:[AB_1834437](nif-antibody:AB_1834437){#interref125}PE-Cyanine7 NKp46 anti-mouse mAb (29A1.4)Thermo FischerCat\# 25-3351-82; RRID:[AB_2573442](nif-antibody:AB_2573442){#interref130}APC Anti-Mouse CD3e mAb (145-2C11)BD BiosciencesCat\# 561826; RRID:[AB_10896663](nif-antibody:AB_10896663){#interref135}APC CD11b mAb (M1/70)BD BiosciencesCat\# 561690; RRID:[AB_10897015](nif-antibody:AB_10897015){#interref140}PE anti-mouse CD27 mAb (LG.3A10)BD BiosciencesCat\# 561785; RRID:[AB_10896150](nif-antibody:AB_10896150){#interref145}PE anti-rat/mouse CD49a mAb (Ha31/8)BD BiosciencesCat\# 562115; RRID:[AB_562115](nif-antibody:AB_562115){#interref150}PE anti-mouse Ly-49C and Ly-49I mAb (5E6)BD BiosciencesCat\# 553277; RRID:[AB_394751](nif-antibody:AB_394751){#interref155}PerCP-Cy5.5 anti-mouse NK-1.1 mAb (PK136)BD BiosciencesCat\# 561111; RRID:[AB_10564092](nif-antibody:AB_10564092){#interref160}BV421 Akt (pS473) mAb (M89-61)BD BiosciencesCat\# 562599; RRID:[AB_2737674](nif-antibody:AB_2737674){#interref165}PE ERK1/2 (pT202/pY204) mAb (20A)BD BiosciencesCat\# 612566; RRID:[AB_399857](nif-antibody:AB_399857){#interref170}Alexa Fluor 647 Stat5 (pY694) mAb (47/Stat5(pY694))BD BiosciencesCat\# 562076; RRID:[AB_11154412](nif-antibody:AB_11154412){#interref175}Brilliant Violet 605 anti-mouse CD45 mAb (30-F11)BioLegendCat\# 103139; RRID:[AB_2562341](nif-antibody:AB_2562341){#interref180}Brilliant Violet 605 anti-mouse CD45.1 mAb (A20)BioLegendCat\# 110737; RRID:[AB_11204076](nif-antibody:AB_11204076){#interref185}PE anti-mouse Ly-49A^B6^ mAb (A1/Ly49A)BioLegendCat\# 138703; RRID:[AB_2134787](nif-antibody:AB_2134787){#interref190}Alexa Fluor 647 anti-mouse Ly49D mAb (4E5)BioLegendCat\# 138306; RRID:[AB_10574955](nif-antibody:AB_10574955){#interref195}Anti-Eomes antibody - ChIP GradeabcamCat\# ab23345; RRID:[AB_778267](nif-antibody:AB_778267){#interref200}Anti-NK1.1 (pk136)WashU Antibody Production CoreN/A**Chemicals, Peptides, and Recombinant Proteins**TamoxifenSigma AldrichCat\# T5648Corn oilSigma AldrichCat\# C8267HyClone Classical Liquid Media: RPMI 1640Thermo FisherCat\# SH30027LSFetal Bovine SerumSigma AldrichCat\# F0926Fixation/Permeabilization ConcentrateInvitrogenCat\# 00-5123-43Fixation/Permeabilization DiluentInvitrogenCat\# 00-5223-56Permeabilization Buffer (10X)InvitrogenCat\#00-8333-56Cytofix/Cytoperm Fixation and Permeabilization SolutionlBD BioscienceCat\# BDB554722murine IL-15PeprotechCat\#210-15Trizol ReagentInvitrogenCat\#15596026Poly (I:C) LMWInvivogenCat\#tlrl-picw7-AADSigma AldrichCat\#A9400Murine IL-12PeprotechCat\#210-12Protein Transport Inhibitor (Containing Brefeldin A)BD BioscienceCat\# 555029Protein Transport Inhibitor (Containing Monensin)BD BioscienceCat\# 554724FxCycle Violet StainInvitrogenCat\#F10347Hyclone L-GlutamineThermo FisherCat\# SH3003402Hyclone HEPES SolutionThermo FisherCat\# SH3023701HyClone Non Essential Amino AcidsThermo FisherCat\# SH3023801HyClone Sodium Pyruvate SolutionThermo FisherCat\# SH3023901HyClone Penicillin Streptomycin 100X SolutionThermo FisherCat\# SV30010**Critical Commercial Assays**FAM-FLICA® Poly Caspase Assay KitImmunochemistry TechnologiesCat\# 9120PE Annexin V Apoptosis Detection KitBD BioscienceCat\# 559763CellTrace Violet Cell Proliferation KitThermo FisherCat\# C34557Direct-zol RNA MicroprepZymo ResearchCat\#R2061EasySep Mouse NK Cell Isolation KitStem Cell TechnologiesCatalog \# 19855**Deposited Data**RNA Seq DataThis paperGEO: [GSE132942](ncbi-geo:GSE132942){#intref0010}Chip Seq DataThis paperGEO: [GSE133048](ncbi-geo:GSE133048){#intref0015}**Experimental Models: Cell Lines**Mouse: RMA-SYokoyama Lab, Wash URRID: CVCL_2180Mouse: YAC-1Yokoyama Lab, Wash URRID: CVCL_2244**Experimental Models: Organisms/Strains**Mouse: Ncr1-ERT2-iCreFehniger Lab, Wash U (This paper)N/AMouse: ROSA26 YFP^lox/stop/lox^The Jackson LaboratoryCat\# JAX:006148; RRID:IMSR_JAX:006148Mouse: Eomes^loxp/loxp^The Jackson LaboratoryCat\# JAX: 017293; RRID:IMSR_JAX:017293Mouse: Eomes^fl/fl^ x Ncr1-ER^T2^-iCre^KI/WT^ x Rosa-YFP^KI/KI^Fehniger Lab, Wash U (This Paper)N/AMouse: Ncr1-ER^T2^-iCre^KI/WT^ x Rosa-YFP^KI/KI^ x Eomes^WT/WT^Fehniger Lab, Wash U (This Paper)N/AMouse: CD45.2 C57BL/6JThe Jackson LaboratoryCat\# JAX: 000664; RRID:IMSR_JAX:000664Mouse: CD45.1 C57BL/6JThe Jackson LaboratoryCat\# JAX: 002014; RRID:IMSR_JAX:002014Mouse: B2m^−/−^Yokoyama Lab, Wash UN/A**Software and Algorithms**FlowJoTreestar Inc<https://www.flowjo.com/>; RRID:[SCR_008520](rridsoftware:SCR_008520){#interref205}NovoalignNovocraft<http://www.novocraft.com/products/novoalign/>; RRID:[SCR_014818](rridsoftware:SCR_014818){#interref210}MACS([@bib52])<https://taoliu.github.io/MACS/>; RRID:[SCR_013291](rridsoftware:SCR_013291){#interref215}STAR version 2.0.4b([@bib10])<https://code.google.com/p/rna-star/>; RRID:[SCR_015899](rridsoftware:SCR_015899){#interref220}Gene Set Enrichment Analysis Software([@bib43]) and ([@bib31])<https://www.gsea-msigdb.org/gsea/index.jsp>; RRID:[SCR_003199](rridsoftware:SCR_003199){#interref225}Subread:feature Count version 1.4.5([@bib25])<http://bioinf.wehi.edu.au/featureCounts/>; RRID:[SCR_009803](rridsoftware:SCR_009803){#interref230}GraphPad Prism 7GraphPad Software<https://www.graphpad.com/scientific-software/prism/>; RRID:[SCR_002798](rridsoftware:SCR_002798){#interref235}

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Todd A. Fehniger (<tfehnige@wustl.edu>).

### Materials Availability {#sec4.2.2}

The *Ncr1*-iCreER^T2^ mouse generated in this study will be made available to qualified investigators by the Lead Contact, Todd A. Fehniger (<tfehnige@wustl.edu>) upon request.

### Data and Code Availability {#sec4.2.3}

The accession numbers for the RNaseq and CHIPseq data reported in this paper are GEO:[GSE132942](ncbi-geo:GSE132942){#interref240} (RNaseq) and GEO:[GSE133048](ncbi-geo:GSE133048){#interref245} (ChIPseq).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

*Ncr1*-iCreER^T2^ mice were developed in the Fehniger lab on the C57BL/6J background. Mice were bred to *Rosa26* YFP^LSL^ knock-in mice (The Jackson Laboratory, stock no. 006148) as well as *Eomes* ^fl/fl^ mice (The Jackson Laboratory, stock no. 017293). For all experiments, ILC-Eomes^Δ/Δ^ refers to *Ncr1*-iCreER^T2\ KI/WT^ x *Rosa26*YFP^LSL^ x *Eomes* ^fl/fl^ mice. *Ncr1*-iCreER^T2\ KI/WT^ x *Rosa26*YFP^LSL^ x *Eomes* ^WT/WT^ mice were used as WT controls in [Figures 1](#fig1){ref-type="fig"}E, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}A, 3B, 3D, 3F, 3G, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}A, and 6B, as well as [Figures S1](#mmc1){ref-type="supplementary-material"} and [S3--S5](#mmc1){ref-type="supplementary-material"}. In the remaining figures, if these mice were limiting, *Ncr1*-iCreER^T2\ WT/WT^ x *Rosa26*YFP^LSL^ x *Eomes* ^fl/fl^ mice as well as CD45.1 and CD45.2 C57BL/6J mice (The Jackson Laboratory, nos. 002014 and 000664) were also utilized. CD45.1 C57BL/6J mice were utilized as WT controls in Figure S6 and as *cre*-negative controls in [Figure S4](#mmc1){ref-type="supplementary-material"}. Rag2^−/−^γc^−/−^ mice (Taconic, no. 4111) were used as recipients for *in vivo* homeostatic proliferation assays ([Figure S4](#mmc1){ref-type="supplementary-material"}). All mice (Eomes WT and ILC-Eomes^Δ/Δ^) were treated with identical tamoxifen regimens for all experiments. Mice were orally gavaged with 3mg tamoxifen (Sigma) in corn oil (Sigma) for 2-3 days as described. Mice were bred and maintained in specific pathogen-free housing, and experiments were conducted in accordance with the guidelines of and with the approval of the Washington University Animal Studies Committee. Experiments were performed on 8-12 week old male and female mice.

### Cell Lines {#sec4.3.2}

RMA-S and YAC-1 cell lines were maintained at 37°C in 5% CO~2~ in RPMI-1640 plus 10% FBS and supplements(10mM HEPES, 1% NEAA, 1% sodium pyruvate, 1% L-glutamine, 1X penicillin and streptomycin) following ATCC guidelines and kept in continuous culture for \< 2 months.

Method Details {#sec4.4}
--------------

### Organ isolation and processing {#sec4.4.1}

Mice were sacrificed by CO~2~ asphyxiation and organs harvested immediately. Blood was harvested by cardiac puncture prior to removal of other organs. Spleens and inguinal nodes were isolated and crushed through a 70 μm filter to generate a single cell suspension. Bone marrow was harvested by flushing femurs with a 23-gauge needle. Whole livers were desiccated with a tissue grinder then lymphocytes were isolated using a Percoll gradient. All tissues were ammonium-chloride-potassium lysed. Cell counts were obtained using propium iodide exclusion with a Cellometer counter (Nexcelcom).

### Flow cytometry and cell sorting {#sec4.4.2}

Surface antibody staining was performed for 15 minutes at 4°C. Intracellular staining was performed in permeabilization buffer following fixation/permeabilization with kits from BD Biosciences (for IFN-γ staining) or Invitrogen (for Eomes, Granzyme B, Bcl2, and Ki67 staining). Eomes^Δ/Δ^ NK cells (and *cre-*positive WT cells) were gated on YFP+ events whenever possible. Since Invitrogen fixation/permeabilization quenches YFP, cells were pre-fixed in 1% PFA for 2 minutes at room temperature prior to fixation/permeabilization in order to preserve YFP when intracellular proteins were assessed after the Tam-6d regimen ([Figures 1](#fig1){ref-type="fig"}E and [2](#fig2){ref-type="fig"}). However, pre-fixation was unable to preserve YFP after the Tam-3d regimen, so intracellular analyses were performed on bulk NK cells (which were nearly 80% YFP+, [Figure 3](#fig3){ref-type="fig"}A) at this time point. For phosphoflow cytometry assays, splenocytes were stimulated with recombinant mouse IL-15 (Peprotech) at 10ng/mL or 100ng/mL for 15 minutes (pSTAT5) or 1 hour (pERK, pAkt). Cells were then fixed with 1% PFA for 10 minutes at room temperature. Next, cells were permeabilized in ice cold methanol for 30 minutes at 4°C, then washed and stained overnight with phosphoflow antibodies. Flow cytometry data were collected on a Gallios flow cytometer (Beckman Coulter) and analyzed using FlowJo (Treestar) software. Cell sorting was performed on a BD FACS Aria II to greater than 95% purity.

### Cell cycle and viability assays {#sec4.4.3}

Cell cycle was assessed using Ki67 and FxCycle Violet (Invitrogen) staining following Invitrogen Fixation/Permeabilization. For viability assays, freshly-isolated splenocytes were incubated at 37°C for 2-3 hours then assayed for poly-caspase activation (Immunochemistry Technologies) or surface Annexin V (performed in Annexin V buffer, both BD Biosciences).

### *In vivo* maturation experiments {#sec4.4.4}

In [Figure 5](#fig5){ref-type="fig"}, ILC-Eomes^Δ/Δ^ and Eomes WT mice were treated with the Tam-3d regimen. Next, NK cells were purified via negative selection (StemCell Technologies, Inc.) from pooled ILC-Eomes^Δ/Δ^ or Eomes WT spleens and sorted to YFP+ stage II/III (CD27+) or stage IV (CD27- CD11b+). Cells were injected into separate male CD45.2 WT recipients. 2 weeks later, mice were sacrificed and the stage distribution of YFP+ splenocytes analyzed via flow cytometry. In Figure S6, NK cells were purified from pooled ILC-Eomes^Δ/Δ^ or CD45.1 WT spleens, labeled with CTV (Invitrogen) and sorted to stage II/III (CD27+) or stage IV (CD27- CD11b+) prior to tamoxifen administration. ILC-Eomes^Δ/Δ^ and Eomes WT cells of the same stage were pooled and injected into male CD45.2 WT mice, who then received 3 daily doses of 3mg tamoxifen in corn oil via oral gavage. 2 weeks later, recipient mice were sacrificed and the stage of CTV+YFP+ (ILC-Eomes^Δ/Δ^) and CTV+CD45.1+ (WT) cells analyzed by flow cytometry.

### *In vivo* homeostatic proliferation {#sec4.4.5}

ILC-Eomes^Δ/Δ^ and Eomes WT mice along with Cre- CD45.1 WT controls were treated with the Tam-3d regimen. Splenocytes were CTV-labeled, then NK cells were purified from pooled splenocytes via negative selection (StemCell Technologies, Inc.) and sorted to NK1.1+CD3-YFP+ (ILC-Eomes^Δ/Δ^ and WT) or NK1.1+CD3- (CD45.1WT). Sorted cells were injected in CD45.2 Rag2^−/−^γc^−/−^ recipients and CTV dilution of YFP+ (ILC-Eomes^Δ/Δ^ and WT) or CD45.1+ cells (CD45.1 WT) was assessed 4 or 14 days post-transfer via flow cytometry.

### ChIP sequencing {#sec4.4.6}

In 3 separate experiments, purified NK cells from pooled CD45.2 Eomes WT splenocytes were expanded *in vitro* for 4 days with 100ng/mL IL-15. Cells were then harvested and approximately 10 × 10^6^ cells were used per ChIP experiment. Chromatin immunoprecipiation was performed using the MAGnify Chromatin Immunoprecipitation System (Thermo Fisher) as per manufacturer's instructions with a ChIP-grade anti-Eomes antibody from Abcam (ab23345). Non-immunoprecipitated DNA was used as an input control. ChIP DNA was blunt ended, had addition of "A" base to 3′ end, and had sequencing adapters ligated to the ends. The fragments were size selected to 200-600 base pairs, and underwent amplification for 15 cycles with primers incorporating p5 and p7 sequences and a unique index tag for multiplexing. The resulting libraries were sequenced using the Illumina HiSeq3000 as single reads extending 50 bases. The raw data was demultiplexed and aligned to the reference genome using Novoalign. MACS was used to call peaks. For downstream analysis, gene-associated peaks that had greater than 5-fold enrichment over input and were present in all three replicates (±500 base pairs from each other) were identified ([Table S1](#mmc2){ref-type="supplementary-material"}).

### RNA sequencing and Gene Set Enrichment Analysis {#sec4.4.7}

In 3 separate experiments, ILC-Eomes^Δ/Δ^ or CD45.2 Eomes WT mice were treated with the Tam-3d regimen. Next, NK cells were purified from pooled ILC-Eomes^Δ/Δ^ or Eomes WT splenocytes and sorted to stage II (CD27+CD11b-), stage III (CD27+CD11b+), or stage IV (CD27-CD11b+). KO cells were also YFP+. Cells were stored in Trizol at −80°C until RNA isolation using the Direct-zol RNA MicroPrep kit (Zymo Research). NextGen RNA sequencing was performed using an Illumina HiSeq 2500 sequencer. RNA-Seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b. Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5. Differential expression analysis was performed to analyze for differences between conditions and the results were filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted p values less than or equal to 0.05.

We utilized Gene Set Enrichment Analysis (GSEA) with the Molecular Signatures Database (MSigDB) ([@bib43], [@bib31]) developed by the Broad Institute and UC San Diego on the RNA sequencing results of sorted stage II, III, and IV ILC-Eomes^Δ/Δ^ and Eomes WT NK cells to identify biological pathways that were enriched or downregulated in ILC-Eomes^Δ/Δ^ versus Eomes WT NK cells in respective maturation stages. Pathways were considered significantly enriched or downregulated if p \< 0.05 and FDR \< 0.25.

### *In vivo* β2 m^−/−^ rejection {#sec4.4.8}

ILC-Eomes^Δ/Δ^ and WT mice were orally gavaged with 3mg tamoxifen in corn oil for 3 consecutive days. On the third day, mice also received 4e6 splenocytes that were a 50/50 mix of CD45.2 WT and β2 m^−/−^ (a gift from Wayne Yokoyama). Transferred splenocytes were differentially labeled with CTV for discrimination. In addition, on the first day of tamoxifen administration, some control mice received 200 μg anti-NK1.1 intraperitoneally (i.p.) to control for non NK-specific killing. 18-20 hours after splenocyte transfer, mice were sacrificed and the ratio of CTV^hi^ (WT) to CTV^low^ (β2 m^−/−^) splenocytes was assessed. Percent rejection was calculated as: (1-\[(Ratio WT:β2 m^−/−^)~experimental~/(Ratio WT:β2 m^−/−^)~NK\ depleted~\])^∗^100 ([@bib34]).

### *In vitro* cytotoxicity (FLoKA) assays {#sec4.4.9}

ILC-Eomes^Δ/Δ^ and WT mice were administered 3mg tamoxifen in corn oil via oral gavage for 2 consecutive days. On the second day, mice were also administered 300 μg of poly I:C (Invivogen) i.p. 20-24 hours post-poly I:C, splenocytes were pooled from 2-3 mice per group and NK cells were enriched via negative selection (Stem Cell Technologies). NK-enriched splenocytes were used in killing assays against CTV-labeled RMA-S targets at the indicated E:T ratios for 4 hours. Dead cells were identified via 7-AAD staining and specific killing calculated as: % 7-AAD+~effector+target~ - % 7-AAD+~target alone~. Mice were cheek bled immediately prior to poly I:C administration for a baseline NK cell granzyme B readout, and splenic NK cell granzyme B was also assessed at the time of the killing assay.

### *In vitro* functional assays {#sec4.4.10}

ILC-Eomes^Δ/Δ^ and Eomes WT mice were treated with the Tam-3d, Tam-6d, and Tam-9d regimens. At each time point, functional assays were performed on splenocytes. Splenocytes were either unstimulated (media alone) or stimulated with cytokines (10ng/mL IL-12 + 10ng/mL IL-15, both Peprotech), YAC-1 lymphoma targets (E:T = 10:1), or plate-bound purified anti-NK1.1 for 6 hours. Anti-CD107a (LAMP-1) antibody was added at the start of the assay to detect degranulation, and brefeldin A and monensin (BD Biosciences) were added for the final 5 hours. Cells were then surface stained, fixed/permeabilized (BD Biosciences), and intracellularly stained for IFN-γ, follow by flow cytometry analysis.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analyses were performed using GraphPad Prism 7 software. Tests utilized are indicated in figure legends. ^∗^ = p \< 0.05, ^∗∗^ = p \< 0.01, ^∗∗∗^ = p \< 0.001.
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